Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
126 studies found for:    "Expanded Access" [STUDY-TYPES] | Open Studies
Show Display Options
Rank Status Study
1 Available Islet Transplant for Type 1 or Surgical Diabetes
Conditions: Type 1 Diabetes Mellitus;   Hypoglycemia;   Labile Diabetes;   End-stage Renal Disease
Intervention: Biological: Allogeneic islets of Langerhans
2 Unknown  Special Access for the Use of Voclosporin for Kidney Transplantation
Conditions: Kidney Transplantation;   Immunosuppression
Intervention: Drug: Voclosporin
3 Available Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Drug: Pirfenidone
4 Available Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
5 Unknown  Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
Conditions: Leishmaniasis, Cutaneous;   Leishmaniasis, Mucocutaneous
Intervention: Drug: sodium stibogluconate (Pentostam)
6 Available Osteopathic Approach Into Neonatology Ward: the NE-O Model
Condition: The Focus of the Study is to Provide a Guideline on Osteopathic Approach in Treating Hospitalized Newborns.
Intervention: Other: Osteopathic Manipulative Treatment
7 Available Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Conditions: Chronic Myeloid Leukemia;   Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Intervention: Biological: G-CSF mobilized CD34+ selected cells for transplantation
8 Unknown  131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
Condition: Neuroblastoma
Intervention: Drug: Metaiodobenzylguanidine (MIBG)
9 Available Long-Term Compassionate Use Study for Continued Administration of SCB01A-01
Condition: Malignant Solid Tumour
Intervention: Drug: SCB01A
10 Available Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Afatinib
11 Unknown  Dolutegravir Expanded Access Study
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: dolutegravir
12 Available Keratoconus and Ectasia Treatment Plan
Conditions: Keratoconus;   Ectasia
Interventions: Other: Riboflavin Solution;   Device: UV-X Illumination System
13 Unknown  Evaluation of the Proliferative Activities of Insulin Analogues in Primary Human Tumor Cells
Conditions: Endometrial Cancer;   Colon Cancer
Intervention: Other: Tissue sample from tumor
14 Available Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan
Condition: Prostate Cancer
Intervention: Drug: [11C]Acetate
15 Available Expanded Access Protocol Thymus Transplantation
Conditions: Poor Thymic Function;   Immunodeficiency;   Athymia;   Immunoreconstitution;   Thymus Transplantation;   Low T Cell Numbers
Interventions: Biological: Thymus Transplantation;   Procedure: Blood Draw;   Drug: Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus
16 Available Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Condition: Hypertension, Pulmonary
Intervention: Drug: Adempas (Riociguat, BAY63-2521)
17 Available Prevention of Transmission of Sexually Transmitted Diseases in the Youth Through Effective Intervention,
Condition: HIV
Intervention: Behavioral: Lifestyle Counseling
18 Available An Open Label Access Study For Subjects Who Completed A1481156
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Access program
19 Available Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents
Conditions: Fanconi Anemia;   Autosomal or Sex Linked Recessive Genetic Disease;   Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases.;   Hematopoiesis Maintainance.
Interventions: Genetic: human whole exome;   Genetic: whole genomic
20 Available Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody (CheckMate 168)
Condition: Stage III (Unresectable) or Stage IV Advanced Melanoma
Intervention: Drug: Nivolumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years